Role of Ischemia-Modified Albumin in Type 2 Diabetes Mellitus,
/ 0
- Details
- Category: Vol. 84, March 2016
- Hits: 754
Role of Ischemia-Modified Albumin in Type 2 Diabetes Mellitus, WAFAA S. ELTAHER, AMER S. MOHAMED, MOHAMED A. EL-DESOUKY, OSAMA H. BEKHEET and HAZEM M. EL-HARIRI
Abstract
Ischemia-modified albumin (IMA) is regarded as a biom-arker of oxidative stress related to ischemia-reperfusion in different clinical conditions associated with oxidative stress, such as chronic kidney disease, hypercholesterolemia, systemic sclerosis and also, as showed on a preliminary report, in type 2 diabetes.
Subjects and Methods: This study included 75 subjects. The study groups were classified into 5 groups: Group 1 (Control): Included 15 normal healthy subjects (10 males & 5 females). Group 2 (Renal): Included 15 patients under renal dialysis (10 males & 5 females). Group 3 (DM): Included 15 diabetic patients with diabetes mellitus type 2 (9 males & 6 females). Group 4 (DM & Renal): Included 15 patients with combined diabetes mellitus type 2 & renal dialysis (8 males & 7 females). Group 5 (HCV): Included 15 patients with chronic hepatitis C infection (8 males & 7 females).
Aim: Evaluation of ischemia-modified albumin (IMA) in patients with type 2 diabetes mellitus, chronic renal failure with heamodialysis and hepatitis C patients.
Results: Mean of IMA highly significantly elevated in group 2 (renal haemodialysis patients) (at p<0.001), followed by group 5 (Hepatitis C patients) (at p<0.001), followed by group 3 (type 2 diabetes patients) (at p<0.001) and group 4 (type 2 diabetes patients with renal haemodialysis) (at p<0.001) compared to control group.
Conclusion: IMA is increased in chronic diseases than control subjects. Our study revealed that IMA is a good however non-specific indicator for chronic conditions (diabetes mellitus type 2, chronic renal failure with haemodialysis and hepatitis C infection).